WallStreetZenWallStreetZen

NASDAQ: CTXR
Citius Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CTXR

Based on 1 analyst offering 12 month price targets for Citius Pharmaceuticals Inc.
Min Forecast
$4.00+445.7%
Avg Forecast
$4.00+445.7%
Max Forecast
$4.00+445.7%

Should I buy or sell CTXR stock?

Based on 1 analyst offering ratings for Citius Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTXR stock forecasts and price targets.

CTXR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-14

1 of 1

Forecast return on equity

Is CTXR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is CTXR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CTXR revenue forecast

What is CTXR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$185.2M
Avg 2 year Forecast
$121.3M
Avg 3 year Forecast
$201.7M

CTXR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTXR$0.73$4.00+445.70%Buy
VOR$1.70$13.50+694.12%Buy
NVCT$6.51N/AN/A
VXRT$0.66$2.00+203.95%Strong Buy
PDSB$3.26$17.33+431.69%Strong Buy
View Top Biotech Stocks

Citius Pharmaceuticals Stock Forecast FAQ

Is Citius Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CTXR) stock is to Buy CTXR stock.

Out of 1 analyst, 0 (0%) are recommending CTXR as a Strong Buy, 1 (100%) are recommending CTXR as a Buy, 0 (0%) are recommending CTXR as a Hold, 0 (0%) are recommending CTXR as a Sell, and 0 (0%) are recommending CTXR as a Strong Sell.

If you're new to stock investing, here's how to buy Citius Pharmaceuticals stock.

What is CTXR's revenue growth forecast for 2024-2026?

(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Citius Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CTXR's revenue for 2024 to be $29,459,580,598, with the lowest CTXR revenue forecast at $29,459,580,598, and the highest CTXR revenue forecast at $29,459,580,598. On average, 1 Wall Street analysts forecast CTXR's revenue for 2025 to be $19,298,196,935, with the lowest CTXR revenue forecast at $19,298,196,935, and the highest CTXR revenue forecast at $19,298,196,935.

In 2026, CTXR is forecast to generate $32,094,190,171 in revenue, with the lowest revenue forecast at $32,094,190,171 and the highest revenue forecast at $32,094,190,171.

What is CTXR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CTXR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CTXR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CTXR price target, the average CTXR price target is $4.00, with the highest CTXR stock price forecast at $4.00 and the lowest CTXR stock price forecast at $4.00.

The Wall Street analyst predicted that Citius Pharmaceuticals's share price could reach $4.00 by Feb 14, 2025. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 445.7% from the current CTXR share price of $0.73.

What is CTXR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CTXR) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.